Precipio and Cardinal Health Sign Distribution Agreement for its HemeScreen® Portfolio of Molecular assays for Cancer
NEW HAVEN, Conn., Feb. 06, 2024 (GLOBE NEWSWIRE) — Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) announces it has entered into a distribution agreement with Cardinal Health for its HemeScreen molecular assay products.
Related news for (PRPO)
- Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting
- Precipio Announces Q1-2025 Shareholder Update Call
- Precipio Announces Q4 and year-end 2024 Shareholder Update Call
- Precipio Achieves Key Q4-2024 Financial Goals: Positive Adjusted EBITDA and Positive Cash Flow (unaudited)
- Precipio grants senior management performance-based awards instead of traditional time-vested ESOPs